DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetic Analysis of Nicotinamide Riboside

Information source: Aarhus University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Participants

Intervention: Nicotinamide riboside (Dietary Supplement)

Phase: Phase 0

Status: Completed

Sponsored by: Aarhus University Hospital


Nicotinamide riboside is a newly discovered vitamin B3. The pharmacokinetics in humans is so far not analyzed.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Serum nicotinamide riboside

Secondary outcome:

serum concentrations of metabolites of nicotinamide riboside

area under the curve for serum nicotinamide riboside

calculation of halftime of serum nicotinamide riboside

calculation of C-max of serum nicotinamide riboside

calculation of t-max of serum nicotinamide riboside


Minimum age: 18 Years. Maximum age: 30 Years. Gender(s): Male.


Inclusion Criteria:

- BMI 18-25, healthy, male,

Exclusion Criteria:

- liver or kidney diseases, other diseases

Locations and Contacts

Medical Research Laboratories, Aarhus University Hospital, Aarhus 8000, Denmark
Additional Information

Starting date: December 2014
Last updated: February 26, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017